NCT01421355View on ClinicalTrials.gov

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Atazanavir

The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT01421355 - A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter